TY - JOUR T1 - Cost-effectiveness analysis of recombinant factor VIII Fc-fusion protein (rFVIIIFc) for the treatment of severe hemophilia A in Italy incorporating real-world dosing and joint health data JO - PharmacoEconomics - Open PY - 2020/03/01 AU - Bullement A AU - McMordie ST AU - Hatswell AJ AU - Li N AU - Wilson K ED - DO - DOI: 10.1007/s41669-019-0158-8 PB - Springer Science and Business Media LLC VL - 4 SP - 133 EP - 142 Y2 - 2025/08/14 ER -